This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

ISSN:2155-6113

Journal of AIDS & Clinical Research

The International Open Access Journal of AIDS & Clinical Research

Editor-in-Chief

Marc H.V. Van Regenmortel
University of Strasbourg, France

Executive Editors

Vincent C. Marconi
Emory University School of Medicine, USA

Han-zhu Qian
Vanderbilt University School of Medicine, USA

Theofilou Paraskevi
Panteion University, Greece

Fatah Kashanchi
George Mason University, USA

Available online at: OMICS Publishing Group (www.omicsonline.org)

This article was originally published in a journal by OMICS Publishing Group, and the attached copy is provided by OMICS Publishing Group for the author's benefit and for the benefit of the author's institution, for commercial/research/educational use including without limitation use in instruction at your institution, sending it to specific colleagues that you know, and providing a copy to your institution's administrator.

All other uses, reproduction and distribution, including without limitation commercial reprints, selling or licensing copies or access, or posting on open internet sites, your personal or institution's website or repository, are requested to cite properly.

Digital Object Identifier: http://dx.doi.org/10.4172/2155-6113.1000205
The Total Lymphocyte Count is a Factor When Using the CD4 Count to Guide HIV Therapy

Peter Hansen*, Dorothy Sylvia, Michelle DeLelys and Frederic Preffer

1Union Biometrica Technologies, Inc., Canaan, USA
2Dorothy Sylvia, PointCare Technologies, Inc., Marlborough Massachusetts, USA
3Michelle DeLelys, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA
4Frederic Preffer, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA

Abstract

Therapy initiation at confirmation of HIV-infection is now medically preferred, which implies that, with adequate financial support, the diagnostic use of T-helper lymphocyte parameters will shift from ART enrollment to tracking therapeutic response. Of the two main therapy tracking parameters, CD4% and the CD4 count, the CD4% parameter is less prone to non-HIV influences. For example, normal CD4% values do not change at all during 17 years of healthy childhood maturation while the CD4 count falls by approximately a factor of three. In mature, HIV-stable persons the CD4 count randomly fluctuates by approximately 12% from day to day in health and by 30% in severe HIV-infection; while CD4% fluctuates by one-third of these amounts respectively. Despite indications such as these that CD4% is the best cell proxy for HIV-related immune status, CD4% is not delineated in adult therapy guidelines and not universally measured by smaller commercial cytometers in resource challenged areas. With only the CD4 count available how might one determine whether a result was subject to factors that would call for a repeat count at a later time? We showed in two populations (African and American) that the normality of the total lymphocyte count was an indicator of the utility of a given CD4 count. High or low lymphocyte counts were strongly related to a high or low CD4 count, which means that factors such as stress and microbial infection that are known to temporarily affect the total lymphocyte count will affect the CD4 count. During HIV therapy the total lymphocyte count should be inclined to normal values and a lymphocyte count that is high or low relative to a patient’s history would call for a repeat CD4 measurement at a later time and, more importantly, qualify the repeat measurement.

Keywords: Immune status; ART; Best cell proxy; CD4%; CD4 count

Introduction

Studies have shown that CD4% is an independent predictor of HIV progression and owing to its stability a useful marker for disease stage [1-3]. The maturation of a healthy child is an example of a long-term physiological change that demonstrates the superior temporal stability of CD4%. The CD4 count for children has a reference range that is markedly age dependent; dropping progressively by a factor of 3 from newborn to 17 years. In contrast, CD4% has a constant reference range over this same period of maturity [4,5]. The observation that CD4% harmonizes the reference ranges for newborns, children, and adults is consistent with the hypothesis that CD4% is a more fundamental parameter than the CD4 count in the face of progressive physiological change.

Physiological factors also cause both the CD4 count and the CD4% to change quasi-cyclically during a 24 hour day for healthy and HIV-infected populations. In healthy controls, the CD4 count changes by approximately 60% from early morning nadir to late at night maximum, while the change in CD4% is 6-fold less [6]. This example of superior CD4% stability provides evidence that it is a more fundamental parameter than the CD4 count in the face of very short term physiological changes within a given day.

Because these diurnal cycles are only quasi-cyclical and are imperfectly repeated, the CD4 count and CD4% exhibit day to day variations even when measured at the same time of day. Such day to day fluctuations in CD4 count range from approximately 12% in healthy persons to approximately 30% for severe HIV infection. In contrast, day-to-day fluctuations in CD4% range from approximately 5% to 10% for these same persons [6,7]. These findings have been recently confirmed with modern laboratory reference systems [8]. The attenuated day-to-day fluctuation of CD4% compared to the CD4 count provides additional evidence that CD4% is a more stable and plausibly more fundamental immune status parameter than the CD4 count.

Recently in this journal, Achhra et al. [9] assumed CD4% to be the best cell-based proxy for HIV disease stage and showed that, with this assumption there could be a very wide range of CD4 count for any given CD4% and that CD4 count thresholds for disease management should not be used interchangeably among different ethnic populations. They found an Asian population to have lower CD4 counts than a Caucasian population for each narrow stratum of CD4%. This study calls into question the sole reliance on CD4 counts for HIV staging and therapy management and raises interest in the utility of CD4%.

Aim

Our new study shows that if CD4% is taken to be the best available cell-based proxy for HIV disease stage, as suggested by Achhra et al. [9], then the wide CD4 count range they observed for any given CD4% is caused by the wide range of total lymphocyte counts that are associated with that value of CD4%. This has implications for HIV staging in large

*Corresponding author: Peter Hansen, Union Biometrica Technologies, Inc., Canaan, NY, USA 12029, Tel: 518 781 3666; Fax 518 781 3659; E-mail: doowph@gmail.com

Received March 15, 2013; Accepted April 17, 2013; Published April 22, 2013


Copyright: © 2013 Hansen P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
populations. Adult testing and treatment guidelines for the developing world cite the CD4 count alone. Until recently, persons with no access to central laboratory facilities have had limited access to devices that measure CD4%; and when CD4% is available it is frequently used only as ancillary information (the exception being for children). An uncritical reliance on the CD4 count without considering the total lymphocyte count is called into question by our study.

Methods

We obtained 1,454 anonymous samples from normal and immunocompromised persons in sub-Saharan Africa and analyzed them using 6 PointCare NOW™ devices and 148 anonymous samples from normal and immunocompromised persons in the United States and analyzed them using a FACSCanto II™ device. Both types of devices reported the CD4 count, CD4%, and the total lymphocyte count for each sample. In the African data set, 675 samples (46%) were from immunocompromised persons and from the United States data set, 61 samples (41%) were from immunocompromised persons. The samples were obtained by venipuncture into vacuum-type EDTA phlebotomy tubes and maintained in liquid form. Samples were analyzed within 6 hours of phlebotomy in both the African study and United States study. The African samples were obtained from a primarily male, nominally healthy population where the main reason for immunosuppression was HIV-infection. The United States samples were obtained from approximately equal numbers of male and female persons where there were various medical factors causing immunosuppression.

Analysis

We plotted CD4% as the X-axis independent variable with the corresponding CD4 count as the Y-axis variable. We used color codes to group the data into three non-contiguous ranges of the total lymphocyte count. The results are shown in Figures 1 and 2. For the three ranges of total lymphocyte count, we used light blue for low (<1,200 lymphocytes/microliter) (10% of samples), mid-normal (1,800 – 2,200 lymphocytes/microliter) (28% of samples) or high (>3,700 lymphocytes/microliter) (4% of samples). These total lymphocyte count ranges were chosen for graphical illustration and do not correspond to sub-Saharan African or United States reference ranges.

Results

Following the cited literature discussed earlier, we took CD4% to be the stable, independent variable for immune status and observed in Figures 1-4 that for each independent value of CD4% there is a range of observed CD4 counts which is influenced by the range of total lymphocyte counts. To illustrate our findings we constructed a CD4%
When we examined the effect of high and low abnormal lymphocyte counts on the range of CD4 counts for a given CD4% the results were as follows. In the African study 4% of samples were outside the normal range for the total lymphocyte count and in the United States study 7% were outside the normal range for the total lymphocyte count (Figures 3 and 4). In the African study, for a CD4% of 17% the mean CD4 count was approximately unchanged (379 cells/μl) from the preceding calculation but the 1SD range for CD4 count expanded to encompass the range from 186 cells/μl to 554 cells/μl. or an increase of a factor of 1.7 in SD. In the United States study the mean CD4 count was 399 cells/μl and the SD expanded by a smaller factor of 1.4 to encompass the range of approximately 261 cells/μl to 537 cells/μl. In certain disease conditions, which may be unrelated to HIV-infection, individuals as well as populations can experience total lymphocyte count variations that exceed the normal range. For these instances, our study results indicated that abnormal variations in the total lymphocyte count biased CD4 counts that are near the threshold for therapy by as much as 180 counts above or below the threshold. As observed above, these biases would not be apparent to a clinician that had only the patient’s CD4 count available for decision making.

By taking CD4% to be the independent variable for immune status our results reveal that in ART programs where only the CD4 count is used for therapy admission and there are no CD4% results or guidelines available, patients with abnormal total lymphocyte counts may not be properly diagnosed. If a total lymphocyte count is available and it is high, low or abnormal based on patient history this count can be used to indicate be re-testing the CD4 count when the total lymphocyte count has returned to normal for that patient.

Discussion

Our report raises important considerations concerning the therapeutic management of HIV in worldwide, remote locations where CD4% and the total lymphocyte count are not routinely available. Recognizing that the CD4 count is affected by many transient factors, guidelines for adult antiretroviral therapy (ART) management frequently suggest that no therapy decision be made without a repeat CD4 count measurement [13]. But how is one to know that the repeat measurement is any more reflective of a change in HIV-related immune status than was the initial measurement? Our report strongly supports the hypothesis that CD4 counts are highly influenced by total lymphocyte counts and, by extension, the variability and degree of abnormality of a repeat total lymphocyte count in a given patient can be used to determine whether the repeat CD4 count is confirmatory or not.

Quantitative studies are required to determine to what extent the number of circulating CD4 lymphocytes for an individual patient in real life has been influenced by the immune response of all lymphocytes to non-HIV related factors. With properly managed ART, HIV is a long-term disease, during the course of which competent lymphocytes continue to perform immunologic tasks; fluctuating substantially in numbers as they do so. If CD4 counts are utilized as parameters for long-term disease progression or ART monitoring these fluctuations must be better understood, or as a practical matter, coupled with CD4% as a possible future international standard for HIV disease management. Patients residing in rural settings should have the same access to total lymphocyte counts or CD4% as have their counterparts living near central laboratories.

The analysis and discussion in this communication strongly supports the proposal that even without computing or directly...
measuring CD4%, clinicians may more confidently answer the question as to whether they have performed sufficient confirmatory CD4 testing by consulting the repeat outcome of confirmatory total lymphocyte counts on another day. A markedly unstable or abnormal total lymphocyte count would indicate the need for more repeats until lymphocyte stability or normality is reached.

**Funding Support**

Partial support was provided by the Naval Health Research Center, Department of Defense Division of HIV/AIDS Prevention Program (DHAPP) under grant number NOO 244-10-1-00076; BA 10-001.

**References**


Submit your next manuscript and get advantages of OMICS Group submissions

**Unique features:**

- User friendly/feasible website-translation of your paper to 50 world’s leading languages
- Audio Version of published paper
- Digital articles to share and explore

**Special features:**

- 250 Open Access Journals
- 20,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, ESCD, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: http://www.omicsonline.org/submission